Connect with us

News

Robbins Arroyo LLP: Menlo Therapeutics Inc. (MNLO) Misled Shareholders According to Class Action

gbafNews28

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Menlo Therapeutics Inc. (NasdaqGS: MNLO) filed a class action complaint against the company’s officers and directors for alleged violations of the Securities Act of 1933 in connection with Menlo’s January 29, 2018 initial public offering (“IPO”). Menlo, a late-stage biopharmaceutical company, develops and commercializes serlopitant for the treatment of itching associated with dermatologic conditions in the United States.

View this information on the law firm’s Shareholder Rights Blog: https://www.robbinsarroyo.com/menlo-therapeutics-inc/

Menlo Accused of Misleading Investors About the Effectiveness of Its Drug

According to the complaint, in its January 2018 IPO, Menlo issued over 8 million shares at $17 per share, raising over $136 million in gross proceeds. In its registration statement, Menlo stated that if the results of its Phase 2 clinical trials for the treatment of pruritus are promising, the company would “rapidly advance into Phase 3 clinical trials” and would use the net proceeds from the IPO to fund such trials. However, well before the IPO, data for the primary outcome measure of the Phase 2 clinical trial had already exposed serlopitant as ineffective and having little or no prospect of Phase 3 clinical trials or approval by the U.S. Federal Drug Administration. On April 8, 2018, Menlo revealed that the data it collected before the IPO did not meet the efficacy endpoints and its drug was therefore not effective. Menlo shares currently trade at only $5.55 per share a 67% decline from the IPO price.

Menlo Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, [email protected], or via the shareholder information form on the firm’s website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Leonid Kandinov
Robbins Arroyo LLP
600 B Street, Suite 1900
San
Diego, CA 92101
[email protected]
(619)
525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

News

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Ultra Petroleum Corp. and Encourages Investors to Contact the Firm

gbafNews28

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of investors that purchased Ultra Petroleum Corp. (Other OTC: UPLCQ, NASDAQ: UPL) common stock between April 3, 2017 and August 8, 2019 (the Class Period). Investors have until November 2, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

Ultra Petroleum is an oil and gas development company with primary assets in the Pinedale and Jonah fields of the Green River Basin of southwest Wyoming. Over 80% of the Companys revenues have historically been derived from the development and sale of natural gas.

On May 14, 2020, Ultra Petroleum filed for bankruptcy protection and is not named as a defendant in the action.

In April 2017, at the beginning of the Class Period, Ultra Petroleum exited a court-supervised reorganization under Chapter 11 of the U.S. Bankruptcy Code. According to defendants, Ultra Petroleum exited the bankruptcy in growth mode. Defendants stated that the Company was poised to maximize the value of its substantial oil and gas deposits (which they valued at $4.19 billion, including $1.5 billion of proved undeveloped reserves) through ramped up production in 2017 and 2018 and that Ultra Petroleum was on track to produce between 290 and 300 billion cubic feet equivalent (Bcfe) in 2017, with 25% production growth over these figures in 2018. Defendants represented that the Company had the financial and production flexibility to weather even a low-commodity-price environment and was set to ramp up well development with 10 rigs operating by 2018 on the back of an estimated $788 million capital budget. Accretive to this plan was the launch of a horizontal well drilling program, which Ultra Petroleum executives claimed was set to significantly expand the production capabilities of the Companys existing wells.

Then, beginning in August 2017, soon after exiting bankruptcy, Ultra Petroleum began issuing a series of revelations demonstrating that it could not grow production by any meaningful amount and that its wells were worth a fraction of the values previously represented. Finally, on August 9, 2019, Ultra Petroleum announced disappointing results for the second quarter of 2019, disclosing that total revenues for the quarter had decreased 18%, that the Companys horizontal well program had been effectively halted, and that it was lowering its 2019 projected capital investments to a range of $260 million to $290 million and annual production to a range of 238 to 244 Bcfe.

On this news, the price of Ultra Petroleum stock declined 31% to just $0.09 per share and continued to fall to just $0.01 per share, 99% below the stocks Class Period high. On August 22, 2019, Ultra Petroleum stock was delisted. And in May 2020, the Company was forced to enter bankruptcy proceedings yet again in order to seek a court-ordered reorganization.

The complaint, filed on September 1, 2020, alleges that these and similar statements issued by defendants during the Class Period were materially false and misleading when made. Throughout the Class Period, defendants, inter alia: (i) materially overstated the value of Ultra Petroleums oil and gas reserves; (ii) materially misrepresented the Companys ability to ramp up production and its financial flexibility; (iii) failed to disclose the Companys extreme sensitivity to even a modest decline in natural gas prices; and (iv) concealed significant setbacks in the Companys vaunted horizontal well drilling program.

If you purchased Ultra Petroleum common stock during the Class Period and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato, Marion Passmore, or Brandon Walker by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

[email protected]

www.bespc.com

Continue Reading

News

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

gbafNews28

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Intercept Pharmaceuticals, Inc. (Intercept or the Company) (NASDAQ: ICPT) investors concerning the Companys possible violations of the federal securities laws.

If you suffered a loss on your Intercept investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/intercept-pharmaceuticals-inc/.

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On October 8, 2020, it was reported that Intercept is facing an investigation from the U.S. Food and Drug Administration over the potential risk of liver injury in patients taking Ocaliva, [Intercepts] treatment for primary biliary cholangitis, a rare, chronic liver disease.

On this news, Intercept’s stock price fell $3.30 per share, or 8.05%, to close at $37.69 per share on October 8, 2020, thereby injuring investors.

Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice: Persons with non-public information regarding Intercept should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About GPM

Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPMs nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPMs lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPMs attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPMs past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barrons, Investors Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles

Charles H. Linehan, 310-201-9150 or 888-773-9224

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

www.glancylaw.com

[email protected]

Continue Reading

News

COVID-19 Impact and Recovery Analysis – Global Medical Thermometers Market 2020-2024 | Evolving Opportunities with American Diagnostic Corp. and Ansell Ltd. | Technavio

gbafNews28

The medical thermometers market is poised to grow by USD 104.82 million during 2020-2024 progressing at a CAGR of over 8% during the forecast period.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis

The report on the medical thermometers market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by frequent outbreak of epidemics.

The medical thermometers market analysis includes product segment and geography landscape. This study identifies the growing availability of advanced medical thermometers as one of the prime reasons driving the medical thermometers market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters

The medical thermometers market covers the following areas:

Medical Thermometers Market Sizing Medical Thermometers Market Forecast Medical Thermometers Market Analysis

Companies Mentioned

  • American Diagnostic Corp.
  • Ansell Ltd.
  • Beurer GmbH
  • Briggs Corp.
  • Citizen Watch Co. Ltd.
  • Exergen Corp.
  • EASYTEM Co. Ltd.
  • OMRON Corp.
  • Paul Hartmann AG
  • Tecnimed Srl

Key Topics Covered:

Executive Summary

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 – 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Digital thermometers – Market size and forecast 2019-2024
  • Liquid filled thermometers – Market size and forecast 2019-2024
  • Market opportunity by Product

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America – Market size and forecast 2019-2024
  • APAC – Market size and forecast 2019-2024
  • Europe – Market size and forecast 2019-2024
  • South America – Market size and forecast 2019-2024
  • MEA – Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers “ Demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • American Diagnostic Corp.
  • Ansell Ltd.
  • Beurer GmbH
  • Briggs Corp.
  • Citizen Watch Co. Ltd.
  • Exergen Corp.
  • EASYTEM Co. Ltd.
  • OMRON Corp.
  • Paul Hartmann AG
  • Tecnimed Srl

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

     

About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com/

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News49 mins ago

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Ultra Petroleum Corp. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has...

gbafNews28 gbafNews28
News60 mins ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an...

gbafNews28 gbafNews28
News1 hour ago

COVID-19 Impact and Recovery Analysis – Global Medical Thermometers Market 2020-2024 | Evolving Opportunities with American Diagnostic Corp. and Ansell Ltd. | Technavio

The medical thermometers market is poised to grow by USD 104.82 million during 2020-2024 progressing at a CAGR of over...

gbafNews28 gbafNews28
News1 hour ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Innate Pharma SA (IPHA) on Behalf of Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an...

gbafNews28 gbafNews28
News1 hour ago

USG ALERT: Shareholder Rights Firm Labaton Sucharow is Investigating USG Corporation (Former NYSE: USG) for Potential Securities Violations and Breach of Fiduciary Duty in Connection with its Merger with Gebr. Knauf Kg (“Knauf”)

Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against...

gbafNews28 gbafNews28
News1 hour ago

Mavenir Announces Postponement of Plans for Initial Public Offering and Listing

Mavenir announced today, the Company has decided to postpone its initial public offering, which was announced on October 6, 2020,...

gbafNews28 gbafNews28
News1 hour ago

Industrial Valves Market Size in Oil and Gas Industry Will Accelerate at 5% CAGR During 2020-2024 | Technavio

Scope of the report This report provides a detailed analysis of the industrial valves market by product (ball valves, plug...

gbafNews28 gbafNews28
News2 hours ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of JPMorgan Chase & Co. (JPM) on Behalf of Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an...

gbafNews28 gbafNews28
News2 hours ago

Film Capacitor Market Will See High Demand for Polyester Film Capacitors During 2020-2024 | Technavio

Scope of the report This report provides a detailed analysis of the film capacitor market by type (polyester film capacitors,...

gbafNews28 gbafNews28
News2 hours ago

Verastem Oncology Announces New Data Published in The Lancet Oncology Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer,...